App-Quantinova.ai

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

Heather A. Wakelee - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial.

Anthony Victor D'Amico - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Head-to-head comparison of single agent (SA) plinabulin (Plin) versus pegfilgrastim (Peg) for the prevention of chemotherapy-induced neutropenia (CIN) in the phase 3 trial PROTECTIVE-1.

Douglas W. Blayney - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chemotherapy-induced neutropenia

Docetaxel

Incidence and severity of systemic allergic reactions (SAR) reported with chemotherapeutic drugs.

Beulah Elsa Thomas - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Metastatic castration-resistant prostate cancer

Docetaxel

Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).

Karen L. Reckamp - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Associations between interaction effects of mutational events and efficient immunotherapy in squamous NSCLC: Results from 373 patients.

Fan Zhang - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Residual of circulating tumor DNA (ctDNA) indicated therapeutic efficacy of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC).

Zhehai Wang - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

The association of renal function with safety and efficacy of cisplatin plus S-1 (CS) therapy and docetaxel plus cisplatin plus S-1 (DCS) therapy in patients with advanced gastric cancer (AGC): An additional analysis of JCOG1013.

Shuichi Hironaka - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Docetaxel

A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

Nikhil Shukla - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

A prospective, randomized, controlled, multicenter study of apatinib combined with S-1 plus docetaxel as adjuvant therapy for locally advanced gastric cancer.

Zhili Shan - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Docetaxel

Incidence of neutropenia in breast cancer patients with administration of mecapegfilgrastim.

Peifen Fu - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Docetaxel

Copy number profiles of primary tumors for risk stratification of advanced prostate cancer: A biomarker study embedded in the multicenter STAMPEDE trial.

Emily Grist - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): Updated results from a phase I/II study.

Yong Fang - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Treatment patterns and characteristics in the second and third-line therapy setting for real-world small cell lung cancer patients.

Patricia Prince - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

Docetaxel

A randomized phase III study comparing carboplatin with nab-paclitaxel versus docetaxel for elderly patients with squamous-cell lung cancer: Capital study.

Yoichiro Hamamoto - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Docetaxel

Randomized phase II study comparing docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma who are refractory to fluoropyrimidine and platinum-based chemotherapy: OGSG1201.

Takayuki Kii - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Docetaxel

Interaction effect between mutational events on predicting efficacious immunotherapy in nonsquamous NSCLC: Results from 1,083 patients.

Fan Zhang - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

An open-label, pharmacokinetic study to determine the bioavailability, safety and tolerability of single dose oral docetaxel in metastatic prostate cancer (mPC) patients treated with IV docetaxel.

Christopher G. C. A. Jackson - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Dynamic 18F-FDG Total body PET Imaging as a predictive marker of induction chemo-immunotherapy response in locally advanced non-small cell lung cancer.

Hui Liu - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Filters

2459 Abstracts